Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (43 quarters reported)
$113M in Q4 2015 → $2B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Revolution Medicines Inc | 24.2% | Unchanged | 2,577,333 | $483M |
| Relay Therapeutics Inc | 15.0% | Added 11% | 16,035,240 | $300M |
| Genedx Holdings Corp | 12.7% | Added 23% | 3,707,164 | $254M |
| Biolife Solutions Inc | 6.6% | Trimmed 22% | 4,655,000 | $131M |
| Illumina Inc | 4.7% | Unchanged | 530,000 | $93.2M |
| Standard Biotools Inc | 3.7% | Unchanged | 88,783,856 | $73M |
| Structure Therapeutics Inc | 3.2% | Unchanged | 1,175,000 | $63.1M |
| Denali Therapeutics Inc | 2.6% | Added 11% | 2,045,000 | $52.6M |
| Neurogene Inc | 2.4% | Added 8.8% | 1,545,361 | $48.6M |
| Beam Therapeutics Inc | 2.3% | Unchanged | 1,350,000 | $46.3M |
| 10x Genomics Inc | 2.0% | Trimmed 54% | 1,050,000 | $40.3M |
| SR Scholar Rock Hldg Corp | 1.8% | Added 90% | 665,000 | $36.6M |
| Personalis Inc | 1.7% | Added 59% | 2,550,000 | $34.2M |
| Grail Inc | 1.6% | Added 109% | 480,000 | $32.8M |
| Guardant Health Inc | 1.4% | Trimmed 41% | 185,000 | $27.8M |
| Maze Therapeutics Inc | 1.3% | Added 11% | 843,857 | $25.2M |
| Hims & Hers Health Inc | 1.2% | Unchanged | 700,000 | $24.3M |
| Alnylam Pharmaceuticals Inc | 1.1% | Unchanged | 75,000 | $22.6M |
| Taysha Gene Therapies Inc | 1.1% | Unchanged | 3,250,000 | $22.1M |
| Agomab Therapeutics Nv | 1.0% | Unchanged | 1,550,000 | $20.1M |
| Septerna Inc | 0.9% | Unchanged | 553,268 | $18.5M |
| PM Parabilis Medicines Inc | 0.9% | New | 645,690 | $17.7M |
| Sionna Therapeutics Inc | 0.9% | New | 400,000 | $17.6M |
| Veracyte Inc | 0.8% | Unchanged | 276,308 | $16.2M |
| AN Adlai Nortye Ltd | 0.7% | Added 132% | 1,250,000 | $14.4M |
| Prime Medicine Inc | 0.6% | Unchanged | 3,167,175 | $11.7M |
| Absci Corporation | 0.6% | Unchanged | 973,260 | $11.3M |
| Quest Diagnostics Inc | 0.5% | Unchanged | 50,000 | $10.6M |
| Sarepta Therapeutics Inc | 0.4% | New | 470,000 | $8.45M |
| UN Uniqure Nv | 0.3% | New | 150,000 | $6.91M |
| Intellia Therapeutics Inc | 0.3% | Unchanged | 355,000 | $6.01M |
| Moderna Inc | 0.3% | Unchanged | 75,000 | $5.25M |
| Disc Medicine Inc | 0.2% | Unchanged | 65,000 | $4.75M |
| Monte Rosa Therapeutics Inc | 0.2% | Unchanged | 186,014 | $4.5M |
| Century Therapeutics Inc | 0.2% | Unchanged | 1,228,190 | $3.01M |
| Contineum Therapeutics Inc | 0.1% | Unchanged | 148,333 | $2.43M |
| BO Bridgebio Oncology Therapeut | 0.1% | Unchanged | 282,312 | $2.15M |
| Editas Medicine Inc | 0.1% | New | 445,000 | $1.44M |
| PB Pacific Biosciences Calif In | 0.1% | Unchanged | 723,767 | $1.22M |
| K Kardigan Inc | 0.1% | New | 50,000 | $1.19M |
| RP Recursion Pharmaceuticals In | 0.0% | Unchanged | 165,323 | $607K |
| Ginkgo Bioworks Holdings Inc | 0.0% | Unchanged | 36,493 | $362K |
| Tenaya Therapeutics Inc | 0.0% | Unchanged | 361,969 | $268K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Genedx Holdings Corp | Added | +700,000 | +$48.1M | 12.7% |
| 10x Genomics Inc | Trimmed | −1,225,000 | −$47M | 2.0% |
| Biolife Solutions Inc | Trimmed | −1,302,165 | −$36.8M | 6.6% |
| Relay Therapeutics Inc | Added | +1,616,666 | +$30.2M | 15.0% |
| Guardant Health Inc | Trimmed | −130,000 | −$19.5M | 1.4% |
| PM Parabilis Medicines Inc | New | +645,690 | +$17.7M | 0.9% |
| Sionna Therapeutics Inc | New | +400,000 | +$17.6M | 0.9% |
| SR Scholar Rock Hldg Corp | Added | +315,000 | +$17.3M | 1.8% |
| Grail Inc | Added | +250,000 | +$17.1M | 1.6% |
| QN Qiagen Nv | Exited | −360,000 | −$14.4M | — |
Showing the 10 largest of 21 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Avidity Biosciences Inc | Exited | −1,000,000 | −$72.1M | — |
| Ars Pharmaceuticals Inc | Exited | −1,600,000 | −$18.6M | — |
| 10x Genomics Inc | Added | +875,000 | +$18.6M | 3.7% |
| Unitedhealth Group Inc | Exited | −50,000 | −$16.5M | — |
| Agomab Therapeutics Nv | New | +1,550,000 | +$16.3M | 1.2% |
| QN Qiagen Nv | New | +360,000 | +$14.4M | 1.1% |
| Relay Therapeutics Inc | Added | +1,415,000 | +$14.1M | 10.9% |
| Grail Inc | New | +230,000 | +$11.9M | 0.9% |
| Dexcom Inc | Exited | −175,000 | −$11.6M | — |
| The Cigna Group | Exited | −40,000 | −$11M | — |
Showing the 10 largest of 27 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Avidity Biosciences Inc | Trimmed | −780,000 | −$56.3M | 4.5% |
| Guardant Health Inc | Added | +280,000 | +$28.6M | 2.4% |
| Structure Therapeutics Inc | Trimmed | −380,000 | −$26.4M | 5.1% |
| 10x Genomics Inc | New | +1,400,000 | +$22.8M | 1.4% |
| Biolife Solutions Inc | Trimmed | −750,000 | −$18.1M | 8.9% |
| Denali Therapeutics Inc | Added | +950,000 | +$15.7M | 1.9% |
| Standard Biotools Inc | Added | +11,225,000 | +$14.4M | 7.1% |
| Relay Therapeutics Inc | Added | +1,662,193 | +$14.1M | 6.8% |
| Dexcom Inc | New | +175,000 | +$11.6M | 0.7% |
| SR Scholar Rock Hldg Corp | New | +260,000 | +$11.5M | 0.7% |
Showing the 10 largest of 21 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Genedx Holdings Corp | Trimmed | −500,000 | −$53.9M | 27.0% |
| Verve Therapeutics Inc | Exited | −4,095,571 | −$46M | — |
| Biolife Solutions Inc | Trimmed | −1,000,000 | −$25.5M | 14.3% |
| Tempus Ai Inc | New | +294,127 | +$23.7M | 2.0% |
| Codexis Inc | Exited | −7,200,000 | −$17.6M | — |
| Sarepta Therapeutics Inc | Exited | −990,097 | −$16.9M | — |
| Ars Pharmaceuticals Inc | New | +1,600,000 | +$16.1M | 1.3% |
| Alnylam Pharmaceuticals Inc | Trimmed | −26,500 | −$12.1M | 2.1% |
| Illumina Inc | Trimmed | −120,000 | −$11.4M | 4.2% |
| Revolution Medicines Inc | Trimmed | −240,600 | −$11.2M | 10.3% |
Showing the 10 largest of 22 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Trimmed | −810,000 | −$29.8M | 9.7% |
| Blueprint Medicines Corp | Exited | −326,378 | −$28.9M | — |
| Biolife Solutions Inc | Trimmed | −1,000,000 | −$21.5M | 15.1% |
| Exact Sciences Corp | Trimmed | −315,000 | −$16.7M | 0.4% |
| Intellia Therapeutics Inc | Exited | −2,000,000 | −$14.2M | — |
| Alnylam Pharmaceuticals Inc | Trimmed | −38,500 | −$12.6M | 2.4% |
| Structure Therapeutics Inc | Added | +525,000 | +$10.9M | 2.3% |
| B Beigene Ltd | Exited | −40,000 | −$10.9M | — |
| 2seventy Bio Inc | Exited | −2,000,000 | −$9.88M | — |
| GH Ge Healthcare Technologies I | Exited | −100,000 | −$8.07M | — |
Showing the 10 largest of 34 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Illumina Inc | Trimmed | −155,000 | −$12.3M | 3.9% |
| Sarepta Therapeutics Inc | Trimmed | −172,717 | −$11M | 4.7% |
| B Beigene Ltd | New | +40,000 | +$10.9M | 0.9% |
| Exact Sciences Corp | Trimmed | −245,000 | −$10.6M | 1.4% |
| Maze Therapeutics Inc | New | +946,357 | +$10.4M | 0.9% |
| GH Ge Healthcare Technologies I | New | +100,000 | +$8.07M | 0.7% |
| Moderna Inc | Exited | −175,000 | −$7.28M | — |
| 4M 4d Molecular Therapeutics In | Exited | −1,150,000 | −$6.41M | — |
| Hims & Hers Health Inc | New | +200,000 | +$5.91M | 0.5% |
| Alnylam Pharmaceuticals Inc | Trimmed | −20,000 | −$5.4M | 2.6% |
Showing the 10 largest of 26 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Trimmed | −415,000 | −$18.2M | 10.8% |
| Neurogene Inc | Added | +770,745 | +$17.6M | 2.0% |
| Veracyte Inc | Trimmed | −390,000 | −$15.4M | 0.7% |
| Septerna Inc | New | +553,268 | +$12.7M | 0.8% |
| Beam Therapeutics Inc | Added | +475,000 | +$11.8M | 2.1% |
| Agios Pharmaceuticals Inc | New | +250,000 | +$8.22M | 0.5% |
| Moderna Inc | New | +175,000 | +$7.28M | 0.5% |
| Moderna Inc | New | +175,000 | +$7.28M | 0.5% |
| Alnylam Pharmaceuticals Inc | Trimmed | −30,000 | −$7.06M | 2.2% |
| FH Fortrea Hldgs Inc | New | +275,000 | +$5.13M | 0.3% |
Showing the 10 largest of 16 changes.
quarter ended September 30, 2024 · filed November 14, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Illumina Inc | Added | +270,000 | +$35.2M | 6.5% |
| Codexis Inc | Added | +6,100,000 | +$18.8M | 1.7% |
| Standard Biotools Inc | Added | +7,295,000 | +$14.1M | 9.2% |
| Revolution Medicines Inc | Trimmed | −292,592 | −$13.3M | 12.4% |
| Pliant Therapeutics Inc | Exited | −1,000,000 | −$10.8M | — |
| Denali Therapeutics Inc | Trimmed | −310,000 | −$9.03M | 1.9% |
| Veracyte Inc | Trimmed | −191,596 | −$6.52M | 1.5% |
| Syndax Pharmaceuticals Inc | Added | +325,000 | +$6.26M | 0.6% |
| Guardant Health Inc | Added | +250,000 | +$5.74M | 0.5% |
| Relay Therapeutics Inc | Added | +802,534 | +$5.68M | 4.4% |
Showing the 10 largest of 21 changes.
Loading...
